Evidence map›Paper›PMID 40883440›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Synthesis, preclinical evaluation, and clinical translation of [

Zihao Chen, Xingyu Mu, Lei Zhang, Zhisheng Jie, Kadeer Tudi, Haoran Liang, Qingxing Liu, Jingze Li, Weixia Chong, Yufeng Mo and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The radiotracer [Annals of nuclear medicine · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zihao Chen *Key Laboratory Project of Guangdong Provincial Department of Education for Ordinary Universities and GDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, 510515, China.
Xingyu Mu *Department of Nuclear Medicine, The Affiliated Hospital of Guilin Medical University, Guilin, 541001, Guangxi, China.
Lei Zhang *Department of Nuclear Medicine, The Affiliated Hospital of Guilin Medical University, Guilin, 541001, Guangxi, China.
Zhisheng JieKey Laboratory Project of Guangdong Provincial Department of Education for Ordinary Universities and GDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, 510515, China.
Kadeer TudiKey Laboratory Project of Guangdong Provincial Department of Education for Ordinary Universities and GDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, 510515, China.
Haoran LiangKey Laboratory Project of Guangdong Provincial Department of Education for Ordinary Universities and GDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, 510515, China.
Qingxing LiuKey Laboratory Project of Guangdong Provincial Department of Education for Ordinary Universities and GDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, 510515, China.
Jingze LiDepartment of Nuclear Medicine, The Affiliated Hospital of Guilin Medical University, Guilin, 541001, Guangxi, China.
Weixia ChongDepartment of Nuclear Medicine, The Affiliated Hospital of Guilin Medical University, Guilin, 541001, Guangxi, China.
Yufeng MoDepartment of Nuclear Medicine, The Affiliated Hospital of Guilin Medical University, Guilin, 541001, Guangxi, China.
Wei FuDepartment of Nuclear Medicine, The Affiliated Hospital of Guilin Medical University, Guilin, 541001, Guangxi, China. Fuwei19700513@163.com.
Ganghua TangKey Laboratory Project of Guangdong Provincial Department of Education for Ordinary Universities and GDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, 510515, China. gtang0224@smu.edu.cn.

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2022A1515010072Guangdong Province Key Laboratory for Green Processing of Natural Products and Product Safety 2021ZDB02Guangzhou Key Research and Development Program of Guangzhou Science and Technology Plan Foundation 2023B03J0529Key Laboratory Project of Guangdong Provincial Department of Education for Ordinary Universities 2024KSYS018Natural Science Foundation of Guangxi Zhuang Autonomous Region 2025GXNSFHA069001the National Key Research and Development Program 2022YFC2403803the National Natural Science Foundation of China 82371996the National Natural Science Foundation of China 82402332the National Natural Science Foundation of China 82460356
6 · The paper itself

Abstract

purposeSomatostatin receptor subtype 2 (SSTR2) is overexpressed in well-differentiated neuroendocrine neoplasms (NENs) and serves as a key target for positron emission tomography (PET) imaging. While SSTR2 agonists such as [

methodsAsp

resultsDocking analysis showed that Asp

conclusion[

Indexed as

Neuroendocrine TumorsPositron-Emission TomographyRadiopharmaceuticalsReceptors, SomatostatinAnimalsCell Line, TumorChemistry Techniques, SyntheticFemaleGallium RadioisotopesHumansMaleMiceMolecular Docking SimulationPositron Emission Tomography Computed TomographyRadiochemistryTissue DistributionGallium-68Gallium RadioisotopesRadiopharmaceuticalsReceptors, Somatostatinsomatostatin receptor 2SSTR2 protein, humanAgonistAntagonistPET/CT imagingPharmacokinetic propertySomatostatin receptor

Identifiers

PMID40883440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.